Intracellular Peptides: from Discovery to Function
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Serine Proteases with Altered Sensitivity to Activity-Modulating
(19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants. -
A Case of Prohormone Convertase Deficiency Diagnosed with Type 2 Diabetes
Turkish CASE REPORT Archives of DOI: 10.14744/TurkPediatriArs.2020.36459 Pediatrics A case of prohormone convertase deficiency diagnosed with type 2 diabetes Gülin Karacan Küçükali1 , Şenay Savaş Erdeve1 , Semra Çetinkaya1 , Melikşah Keskin1 , Ayşe Derya Buluş2 , Zehra Aycan1 1Department of Pediatric Endocrinology, University of Health Science, Dr. Sami Ulus Obstetrics and Gynecology, Children’s Health and Disease Training and Research Hospital, Ankara, Turkey 2Department of Pediatric Endocrinology, University of Health Science, Keçiören Training and Research Hospital, Ankara, Turkey What is already known ABSTRACT on this topic? Prohormone convertase 1/3, encoded by the proprotein convertase subtilisin/kexin type 1 gene, • Prohormone convertase defi- is essential for processing prohormones; therefore, its deficiency is characterized by a defi- ciency is characterized by a de- ciency of variable levels in all hormone systems. Although a case of postprandial hypoglycemia ficiency of variable levels in all has been previously reported in the literature, prohormone convertase insufficiency with type hormone systems. 2 diabetes mellitus has not yet been reported. Our case, a 14-year-old girl, was referred due to • Postprandial hypoglycemia is a excess weight gain. She was diagnosed as having type 2 diabetes mellitus based on laboratory disorder of glucose metabolism test results. Prohormone convertase deficiency was considered due to the history of resistant reported in this disease. diarrhea during the infancy period and her rapid weight gain. Proinsulin level was measured as >700 pmol/L(3.60-22) during diagnosis. In genetic analysis, a c.685G> T(p.V229F) homozygous mutation in the PCSK1 gene was detected and this has not been reported in relation to this dis- order. -
1 No. Affymetrix ID Gene Symbol Genedescription Gotermsbp Q Value 1. 209351 at KRT14 Keratin 14 Structural Constituent of Cyto
1 Affymetrix Gene Q No. GeneDescription GOTermsBP ID Symbol value structural constituent of cytoskeleton, intermediate 1. 209351_at KRT14 keratin 14 filament, epidermis development <0.01 biological process unknown, S100 calcium binding calcium ion binding, cellular 2. 204268_at S100A2 protein A2 component unknown <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 3. 33323_r_at SFN stratifin/14-3-3σ binding <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 4. 33322_i_at SFN stratifin/14-3-3σ binding <0.01 structural constituent of cytoskeleton, intermediate 5. 201820_at KRT5 keratin 5 filament, epidermis development <0.01 structural constituent of cytoskeleton, intermediate 6. 209125_at KRT6A keratin 6A filament, ectoderm development <0.01 regulation of progression through cell cycle, extracellular space, cytoplasm, cell proliferation, protein kinase C inhibitor activity, protein domain specific 7. 209260_at SFN stratifin/14-3-3σ binding <0.01 structural constituent of cytoskeleton, intermediate 8. 213680_at KRT6B keratin 6B filament, ectoderm development <0.01 receptor activity, cytosol, integral to plasma membrane, cell surface receptor linked signal transduction, sensory perception, tumor-associated calcium visual perception, cell 9. 202286_s_at TACSTD2 signal transducer 2 proliferation, membrane <0.01 structural constituent of cytoskeleton, cytoskeleton, intermediate filament, cell-cell adherens junction, epidermis 10. 200606_at DSP desmoplakin development <0.01 lectin, galactoside- sugar binding, extracellular binding, soluble, 7 space, nucleus, apoptosis, 11. 206400_at LGALS7 (galectin 7) heterophilic cell adhesion <0.01 2 S100 calcium binding calcium ion binding, epidermis 12. 205916_at S100A7 protein A7 (psoriasin 1) development <0.01 S100 calcium binding protein A8 (calgranulin calcium ion binding, extracellular 13. -
Papel De Los Receptores De Estrógenos Alfa En El Crecimiento De Carcinomas Mamarios Murinos Con Respuesta Diferencial a Progestágenos
Tesis Doctoral Papel de los receptores de estrógenos alfa en el crecimiento de carcinomas mamarios murinos con respuesta diferencial a progestágenos Giulianelli, Sebastián Jesús 2009 Este documento forma parte de la colección de tesis doctorales y de maestría de la Biblioteca Central Dr. Luis Federico Leloir, disponible en digital.bl.fcen.uba.ar. Su utilización debe ser acompañada por la cita bibliográfica con reconocimiento de la fuente. This document is part of the doctoral theses collection of the Central Library Dr. Luis Federico Leloir, available in digital.bl.fcen.uba.ar. It should be used accompanied by the corresponding citation acknowledging the source. Cita tipo APA: Giulianelli, Sebastián Jesús. (2009). Papel de los receptores de estrógenos alfa en el crecimiento de carcinomas mamarios murinos con respuesta diferencial a progestágenos. Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Cita tipo Chicago: Giulianelli, Sebastián Jesús. "Papel de los receptores de estrógenos alfa en el crecimiento de carcinomas mamarios murinos con respuesta diferencial a progestágenos". Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. 2009. Dirección: Biblioteca Central Dr. Luis F. Leloir, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires. Contacto: [email protected] Intendente Güiraldes 2160 - C1428EGA - Tel. (++54 +11) 4789-9293 UNIVERSIDAD DE BUENOS AIRES FACULTAD DE CIENCIAS EXACTAS Y NATURALES Departamento de Fisiología, Biología Molecular y Celular PAPEL DE LOS RECEPTORES DE ESTRÓGENOS ALFA EN EL CRECIMIENTO DE CARCINOMAS MAMARIOS MURINOS CON RESPUESTA DIFERENCIAL A PROGESTÁGENOS Tesis presentada para optar por el título de Doctor de la Universidad de Buenos Aires en el área Ciencias Biológicas Sebastián Jesús Giulianelli Director de Tesis: Claudia L. -
Electronic Supplementary Material (ESI) for Analyst. This Journal Is © the Royal Society of Chemistry 2020
Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 Table S1. -
1.2.Obesity-Pathophysiology.Pdf
What Is the Disease of Obesity? Obesity Pathophysiology Obesity Has Multiple Pathophysiologic Origins Epigenetic Environmental Genetic Obesity Sociocultural Physiologic Behavioral Bray GA, et al. Lancet. 2016;387:1947-1956. 2 Obesity Pathophysiology Genetic and Epigenetic Origins 3 Genetic Determinants of Obesity Supported by Genome-Wide Association Studies Gene Tissue expressed Gene product / role in energy balance MC4R Adipocyte, hypothalamus, liver Melanocortin 4 receptor / Appetite stimulation; monogenic cause of obesity ADRB3 Visceral adipose tissue β3-Adrenergic receptor / Regulates lipolysis PCSK1 Neuroendocrine cells (brain, Proprotein convertase 1 / Conversion of hormones (including insulin) pituitary and adrenal glands) into metabolically active forms BDNF Hypothalamus Brain-derived neurotrophic factor / Appetite stimulation; regulated by MC4R signaling and nutritional state LCT Intestinal epithelial cells Lactase / Digestion of lactose MTNR1B Nearly ubiquitous Melantonin receptor 1 B / Regulation of circadian rhythms TLR4 Adipocyte, macrophage Toll-like receptor 4 / Lipolysis, inflammatory reactions ENPP1 Nearly ubiquitous Ecotnucleotide pyrophosphatase/phosphodiesterase 1 / Inhibits tyrosine kinase activity of the insulin receptor, downregulating insulin signaling and decreasing insulin sensitivity FGFR1 Adipose, hypothalamus Fibroblast growth factor receptor 1 / Hypothalamic regulation of food intake and physical activity LEP, LEPR Adipocyte Leptin, leptin receptor / Appetite inhibition den Hoed M, Loos RJF. In: Bray GA, Bouchard -
Discovery of an Allosteric Site on Furin, Contributing to Potent Inhibition: a Promising Therapeutic for the Anemia of Chronic Inflammation
Brigham Young University BYU ScholarsArchive Theses and Dissertations 2014-07-01 Discovery of an Allosteric Site on Furin, contributing to Potent Inhibition: A Promising Therapeutic for the Anemia of Chronic Inflammation Andrew Jacob Gross Brigham Young University Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Chemistry Commons BYU ScholarsArchive Citation Gross, Andrew Jacob, "Discovery of an Allosteric Site on Furin, contributing to Potent Inhibition: A Promising Therapeutic for the Anemia of Chronic Inflammation" (2014). Theses and Dissertations. 6537. https://scholarsarchive.byu.edu/etd/6537 This Dissertation is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected]. Discovery of an Allosteric Site on Furin, Contributing to Potent Inhibition: A Promising Therapeutic for the Anemia of Chronic Inflammation Andrew J. Gross A dissertation submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Doctor of Philosophy Richard K. Watt, Chair Dixon J. Woodbury Roger G. Harrison Chad R. Hancock John T. Prince Department of Chemistry and Biochemistry Brigham Young University July 2014 Copyright © 2014 Andrew J. Gross All Rights Reserved ABSTRACT Discovery of an Allosteric site on Furin, Contributing to potent Inhibition: A promising Therapeutic for the Anemia of Chronic Inflammation Andrew J. Gross Department of Chemistry and Biochemistry, BYU Doctor of Philosophy Anemia of chronic inflammation (ACI) is a condition that develops in a setting of chronic immune activation. ACI is characterized and triggered by inflammatory cytokines and the disruption of iron homeostasis. -
PCSK9 Biology and Its Role in Atherothrombosis
International Journal of Molecular Sciences Review PCSK9 Biology and Its Role in Atherothrombosis Cristina Barale, Elena Melchionda, Alessandro Morotti and Isabella Russo * Department of Clinical and Biological Sciences, Turin University, I-10043 Orbassano, TO, Italy; [email protected] (C.B.); [email protected] (E.M.); [email protected] (A.M.) * Correspondence: [email protected]; Tel./Fax: +39-011-9026622 Abstract: It is now about 20 years since the first case of a gain-of-function mutation involving the as- yet-unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 (PCSK9), was described. It was soon clear that this protein would have been of huge scientific and clinical value as a therapeutic strategy for dyslipidemia and atherosclerosis-associated cardiovascular disease (CVD) management. Indeed, PCSK9 is a serine protease belonging to the proprotein convertase family, mainly produced by the liver, and essential for metabolism of LDL particles by inhibiting LDL receptor (LDLR) recirculation to the cell surface with the consequent upregulation of LDLR- dependent LDL-C levels. Beyond its effects on LDL metabolism, several studies revealed the existence of additional roles of PCSK9 in different stages of atherosclerosis, also for its ability to target other members of the LDLR family. PCSK9 from plasma and vascular cells can contribute to the development of atherosclerotic plaque and thrombosis by promoting platelet activation, leukocyte recruitment and clot formation, also through mechanisms not related to systemic lipid changes. These results further supported the value for the potential cardiovascular benefits of therapies based on PCSK9 inhibition. Actually, the passive immunization with anti-PCSK9 antibodies, evolocumab and alirocumab, is shown to be effective in dramatically reducing the LDL-C levels and attenuating CVD. -
PACE4 Expression in Mouse Basal Keratinocytes Results in Basement Membrane Disruption and Acceleration of Tumor Progression
Research Article PACE4 Expression in Mouse Basal Keratinocytes Results in Basement Membrane Disruption and Acceleration of Tumor Progression Daniel E. Bassi,1,3 Ricardo Lopez De Cicco,1 Jonathan Cenna,1 Samuel Litwin,2 Edna Cukierman,2 and Andres J.P. Klein-Szanto1,3 Departments of 1Pathology and 2Biomathematics and Biostatistics, and 3Tumor Cell Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania Abstract and studying the in vivo effects after overexpressing genes, such as h Collagen type IV degradation results in disruption and transforming growth factor- (3), epidermal growth factor receptor breakdown of the normal basement membrane architecture, (4), and insulin-like growth factor (5). a key process in the initiation of tumor microinvasion into the Proprotein convertases constitute a family of serine proteases that activate their cognate substrates by limited proteolysis at consensus connective tissue. PACE4, a proprotein convertase, activates # membrane type matrix metalloproteinases (MT-MMPs) that in sequence RXR/KR (6). Many of these, such as insulin-like growth turn process collagenase type IV. Because PACE4 is overex- factor-I (7) and its receptor (8), membrane-type matrix metal- pressed in skin carcinomas and in vitro overexpression of loproteinase (MT-MMP; refs. 9, 10), and integrins (11–14) have direct PACE4 resulted in enhanced invasiveness, we investigated roles in tumor progression and metastasis. Although proprotein whetherornotin vivo PACE4 expression leads to the convertases recognize and cleave a specific sequence, variations in the amino acid sequences that surround this motif, as well as acquisition of invasiveness and increased tumorigenesis. Two transgenic mouse lines were designed by targeting PACE4 to preferences in K or R preceding the COOH-terminal R, account for the epidermal basal keratinocytes. -
Investigations Into the Role of Orexin (Hypocretin) and Dynorphin in Drug Seeking, Reinforcement, and Withdrawal ______
INVESTIGATIONS INTO THE ROLE OF OREXIN (HYPOCRETIN) AND DYNORPHIN IN DRUG SEEKING, REINFORCEMENT, AND WITHDRAWAL ________________________________________________________________________ A Dissertation Submitted to Temple University Graduate Board In partial fulfillment of the Requirement of the Degree DOCTOR OF PHILOSPHY By Taylor A. Gentile May 2018 Examining Committee Members: John W Muschamp, PhD, Center for Substance Abuse Research, Advisory Chair, Department of Pharmacology Sara Jane Ward, PhD, Center for Substance Abuse Research, Dept. of Pharmacology Ronald Tuma, PhD, Center for Substance Abuse Research, G.H. Stewart Professor, Physiology Scott M. Rawls, PhD, Center for Substance Abuse Research, Dept. of Pharmacology Shin Kang, PhD, Shriners Hospital Pediatric Research Center, Dept. of Anatomy & Cell Biology Lee Yuan Liu-Chen, PhD, Center for Substance Abuse Research, Dept. of Pharmacology Rodrigo España, PhD, Drexel University College of Medicine, Dept. of Neurobiology & Anatomy i © Copyright 2017 by Taylor A. Gentile All Rights Reserved ii ABSTRACT Psychostimulant dependence remains a major health and economic problem, leading to premature death and costing $181 billion annually in health care, crime, and lost productivity costs. Currently, no pharmacotherapies are available to effectively treat psychostimulant dependence. Psychostimulants cause changes in neural circuits involved in reward and affect, but addiction neurocircuitry is incompletely understood and new targets for therapeutic intervention are needed. Lateral hypothalamic -
(12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov. -
Genetic Deficiency for Proprotein Convertase Subtilisin&Sol
International Journal of Obesity (2010) 34, 1599–1607 & 2010 Macmillan Publishers Limited All rights reserved 0307-0565/10 www.nature.com/ijo ORIGINAL ARTICLE Genetic deficiency for proprotein convertase subtilisin/kexin type 2 in mice is associated with decreased adiposity and protection from dietary fat-induced body weight gain YAnini1,2,JMayne3,JGagnon1,2,JSherbafi3,AChen3,NKaefer3,MChre´tien3,4,5 and M Mbikay3,4,5 1Department of Physiology and Biophysics, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; 2Department of Obstetrics and Gynecology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; 3Chronic Disease Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; 4Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada and 5Division of Endocrinology and Metabolism, Ottawa Hospital, Ottawa, Ontario, Canada Background: Proprotein convertase subtilisin/xexin type 2 (PCSK2) is an endoproteinase responsible for proteolytic activation of a number of precursors to active neuropeptides and peptide hormones, known to influence glucose homeostasis, food intake and ultimately body mass. In this study, we examined the consequences of PCSK2 deficiency on these phenotypic traits. Study Design: Weight gain with age under diets of different fat contents was monitored. White adipose tissue (WAT) and muscle masses were evaluated. Plasma levels of triglycerides, leptin, ghrelin, insulin and proglucagon-derived peptides were measured as well as leptin and acetyl coenzyme-a carboxylase (ACCa) mRNA levels in adipose tissue. Results: Compared with their Pcsk2 þ / þ littermates, Pcsk2À/À mice weighed significantly less as weanlings and as adults. As adults, they carried noticeably less fat mass, with similar lean muscle mass: their plasma leptin level and adipose tissue leptin mRNA level were accordingly lower.